We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics
Product News

Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics

Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics
Product News

Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Horizon Discovery Offers CHOSOURCE™ Platform for COVID-19-related Therapeutics and Diagnostics"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery, a company specializing in the application of gene editing and gene modulation for cell line engineering, has announced special commercial licensing terms to facilitate rapid access to its cGMP-compliant CHOSOURCE™ platform for the development or production of therapeutic proteins, diagnostic assay components or vaccines relating to COVID-19.

The CHOSOURCE platform includes a gene-edited Glutamine Synthetase (“GS”) knockout Chinese Hamster Ovary (CHO) K1 cell line, a well-established GS expression system recognized in the industry and by regulators as suitable for high yield biomanufacturing. The platform is already offered as a royalty-free alternative for the production of complex proteins and is empowering organizations from early stage start-ups to large pharmaceutical companies to drive efficiencies throughout development and production. CHOSOURCE has been utilized in multiple successful Innovative New Drug (IND) filings.

Terry Pizzie, CEO, Horizon Discovery said: “We are committed to providing flexible, royalty-free access licensing terms and solutions that streamline development and production processes. Building upon more than a decade of experience in cell line engineering, we developed our CHOSOURCE cell line and now support a growing number of pharmaceutical companies in bioproduction. We are doing all that we can to support the fight against COVID-19 and hope that offering rapid access to our CHOSOURCE platform will help to accelerate the development and validation of new therapies to combat the pandemic.”

Advertisement